Trial Profile
A Randomized, Double-Blind, Two Way Cross-Over, Proof of Concept Study to Compare the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Two-Week Oral Administration of QAV680 Versus Placebo, With an Extended Open-Label Inhaled Corticosteroid Period, in Steroid-Free, Mild to Moderate Persistent Asthma Patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Nov 2019
Price :
$35
*
At a glance
- Drugs QAV 680 (Primary) ; Fluticasone propionate
- Indications Asthma
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis
- 21 Apr 2012 New source identified and integrated (EudraCT2008-005168-15: European Clinical Trials Database).
- 03 Feb 2011 New source identified and integrated (Clinical Trials Registry - India, CTRI2009-091-000282).
- 22 Sep 2010 Actual end date (October 2009) added as reported by ClinicalTrials.gov.